TY - JOUR T1 - Antiplatelet therapy at discharge and long-term prognosis in Takotsubo syndrome: Insights from the Spanish National Registry (RETAKO) JO - Revista Portuguesa de Cardiologia T2 - AU - Pereyra,Eduardo AU - Fernández-Rodríguez,Diego AU - González-Sucarrats,Silvia AU - Almendro-Delia,Manuel AU - Martín,Agustín AU - de Miguel,Irene Martin AU - Andrés,Mireia AU - Duran-Cambra,Alberto AU - Sánchez-Grande-Flecha,Alejandro AU - Worner-Diz,Fernando AU - Núñez-Gil,Iván J. SN - 08702551 M3 - 10.1016/j.repc.2021.06.029 DO - 10.1016/j.repc.2021.06.029 UR - https://revportcardiol.org/pt-antiplatelet-therapy-at-discharge-long-term-articulo-S0870255122003596 AB - IntroductionEndothelial dysfunction and platelet activation have been highlighted as possible mediators in Takotsubo syndrome (TTS). Nevertheless, to date, evidence on the usefulness of antiplatelet therapy in TTS remains controversial. The aim of our study is to evaluate long-term prognosis in TTS patients treated with antiplatelet therapy (APT) at hospitalization discharge. Material and methodsAn ambispective cohort study from the Spanish National Takotsubo Registry database was performed (June 2002 to March 2017). Patients were divided into two groups: those who received APT at hospital discharge (APT cohort) and those who did not (non-APT cohort). Primary endpoint was all-cause death. Secondary endpoints included the composite of recurrence or readmission and a composite of death, recurrence or readmission. ResultsFrom a total of 741 patients, 728 patients were alive at discharge. Follow-up was performed in 544 patients, who were included in the final analysis: 321 patients (59.0%) in the APT cohort and 223 patients (41.0%) in the non-APT cohort. The APT cohort had a better clinical presentation and received more heart failure and acute coronary syndrome-like therapies (angiotensin converting enzyme inhibitors/angiotensin receptor blockers: 75.1% vs. 51.1%; p<0.001, betablockers: 71.3% vs. 50.7%; p<0.001, statins: 67.9% vs. 33.2%; p<0.001). After adjusting for confounder factors, APT at discharge was a protective factor for all-cause death (adjusted hazard ratio (HR) 0.315, 95% confidence interval (CI): 0.106-0.943; p=0.039) and the composite endpoint of all-cause death, recurrence or readmission (adjusted HR 0.318, 95% CI: 0.164-0.619; p=0.001) at month 25 of follow-up. ConclusionPatients with TTS receiving APT at discharge presented better prognosis up to two-years of follow-up compared with their counterparts not receiving APT. ER -